Organization (Industry)
ELUTIA INC.
ClinicalTrials.gov lists ELUTIA INC. as lead sponsor of 14 trials. It has 3 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers ELUTIA INC.: 14 lead-sponsored trials and 1 legal-entity registration.
Disease areas (9)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Coronary Disease | 3 |
| Intervertebral Disc Degeneration | 2 |
| Spondylolisthesis | 2 |
| Spondylosis | 2 |
| Breast Neoplasms | 1 |
Showing 5 of 9 disease areas.
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2015 | 3 |
| 2014 | 1 |
| 2012 | 1 |
| 2010 | 1 |
Recruitment duration, a model prediction: none of the 14 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (3)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Demineralized Bone Matrix | Spondylolisthesis | Not reported | 1 |
| Demineralized Bone Matrix | Spondylosis | Not reported | 1 |
| Demineralized Bone Matrix | Intervertebral Disc Degeneration | Not reported | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 29% hit target (n=7) | 33% on time (n=6) |
Journals published in (3)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Frontiers in cardiovascular medicine | 1 |
| Journal of cardiothoracic surgery | 1 |
| Journal of orthopaedic surgery and research | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2 | 1 | 2025-03-11 |
SEC-reported annual financials (8)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | not reported | 53,380,000 | 4,163,000 |
| 2024 | not reported | -53,949,000 | 2,998,000 |
| 2023 | not reported | -37,656,000 | 4,399,000 |
| 2022 | not reported | -32,897,000 | 7,727,000 |
| 2021 | not reported | -24,832,000 | 9,266,000 |
| 2020 | not reported | -21,825,000 | 5,954,000 |
| 2019 | not reported | -11,939,000 | 2,400,000 |
| 2018 | not reported | not reported | not reported |
Financing and grant events (49)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-07-16 | Other financing | not disclosed | Sec extracted |
| 2026-07-16 | Other financing | not disclosed | Sec extracted |
| 2025-10-01 | Other financing | 80 | Sec extracted |
| 2025-10-01 | Debt financing | not disclosed | Sec extracted |
| 2025-10-01 | Royalty / licensing | not disclosed | Sec extracted |
Showing 5 of 49 events.
FDA recalls (2)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| BioEnvelope, surgical mesh envelope. Labeled as the following: 1. BioEnvelope (Medium) (single pack); 2. BioEnvelope (Large) (single pack); 3. BioEnvelope (Extra Large) (single pack); 4. BioEnvelope (Extra Extra Large) (single pack); 5. BioEnvelope (Large) (5-pack); 6. BioEnvelope (Medium) (5-pack); 7. BioEnvelope (Extra Extra Large) (5-pack); 8. BioEnvelope (Extra Large) (5-pack) Product Usage: The BioEnvelope is intended to securely hold a cardiac implantable electronic device to create a stable environment when implanted in the body. The cardiac implantable electronic devices that may be used with the CanGaroo Envelope include pacemaker pulse generators, defibrillators, or other cardiac implantable electronic devices. | Class II | 2019-08-21 |
| CanGaroo Envelopes labeled as the following: 1. CanGaroo Envelope (Large) (single pack); 2. CanGaroo Envelope (Medium) (single pack); 3. CanGaroo Envelope (Extra Large) (single pack); 4. CanGaroo Envelope (Extra Extra Large) (single pack); 5. CanGaroo Envelope (Large) (5 pack); 6. CanGaroo Envelope (Medium) (5 pack); 7. CanGaroo Envelope (Extra Large) (5 pack); 8. CanGaroo Envelope (Extra Extra Large) (5 pack) Product Usage: The CanGaroo Envelope is intended to securely hold a cardiac implantable electronic device or an implantable neurostimulator to create a stable environment when implanted in the body. The cardiac implantable electronic devices that may be used with the CanGaroo Envelope include pacemaker pulse generators, defibrillators, or other cardiac implantable electronic devices. The implantable neurostimulator devices that may be used with the CanGaroo Envelope include vagus nerve stimulators, spinal cord neuromodulators, deep brain stimulators and sacral nerve stimulators. | Class II | 2019-08-21 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| ELUTIA INC. | Gaithersburg, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (67)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-16 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-07-16 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-10-01 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-10-01 | Royalty / licensing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-10-01 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 67 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| AZIYO BIOLOGICS, INC | Certificate of compliance | Terminated |
Biomarker capability evidence (12)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| MMRN1 | Trial sponsor | Named in trial inclusion criteria |
| MMRN1 | Trial sponsor | Named in trial inclusion criteria |
| MMRN1 | Trial sponsor | Named in trial inclusion criteria |
| MMRN1 | Trial sponsor | Named in trial inclusion criteria |
| MMRN1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 12 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, fda warning letters, fda untitled letters, fda inspection record, fda import refusals, organization relationships, and biomarkers this organization publishes on.